Cyclophosphamide (generic), Cytoxan Newswire

Cyclophosphamide (generic), Cytoxan Newswire

Comprehensive Real-Time News Feed for Cyclophosphamide (generic), Cytoxan.

Results 1 - 20 of 224 in Cyclophosphamide (generic), Cytoxan

  1. Kiadis Pharma To Present Information On The Design Of Its Phase III...Read the original story

    Wednesday Mar 15 | BioSpace

    In addition, Kiadis Pharma will host a satellite symposium on March 26, 2017 entitled: "Advances in Haploidentical Stem Cell Transplantation and Post-Transplant Immunotherapy". The symposium will be chaired by Dr. Hermann Einsele, Professor at the University Hospital of the Julius-Maximilians-University, WA1 4rzburg, Germany and he will be joined by several other international key opinion leaders in the field of hematopoietic stem cell transplantation.

    Comment?

  2. Kite Pharma Highlights Publication From NCI Demonstrating Durable...Read the original story

    Tuesday Mar 14 | BioSpace

    Kite Pharma, Inc. today highlighted the publication of results in the Journal of Clinical Oncology from a National Cancer Institute study of anti-CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory non-Hodgkin lymphoma . The research, led by James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI Center for Cancer Research, was performed pursuant to a CRADA between NCI and Kite.

    Comment?

  3. TapImmune Provides Year End 2016 Corporate and Clinical UpdateRead the original story

    Tuesday Mar 14 | BioSpace

    Completed first safety cohort in Memorial Sloan Kettering-sponsored Phase 2 combination study with AstraZeneca's durvalumab in platinum-resistant ovarian cancer; now more than 50% enrolled Announced second U.S. Dept. of Defense-funded Phase 2 breast cancer study; Mayo Clinic to vaccinate women with ductal carcinoma in situ using HER2-targeted T-cell vaccine TapImmune, Inc. , a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today provided its first quarterly business update, following the company's uplisting to The NASDAQ Capital Market in the fourth quarter 2016.

    Comment?

  4. Kite Pharma Highlights Publication from the National Cancer Institute ...Read the original story

    Tuesday Mar 14 | Customer Interaction Solutions

    Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy Kite Pharma, Inc. today highlighted the publication of results in the Journal of Clinical Oncology from a National Cancer Institute study of anti-CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory non-Hodgkin lymphoma . The research, led by James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI Center for Cancer Research, was performed pursuant to a CRADA between NCI and Kite.

    Comment?

  5. Adaptimmune Therapeutics' (ADAP) CEO James Noble on Q4 2016 Results - Earnings Call TranscriptRead the original story w/Photo

    Monday Mar 13 | Seeking Alpha

    Good day and welcome to the Adaptimmune Fourth Quarter Financial Results Conference Call. Today's conference is being recorded and at this time, I would like to turn the conference over to Mr. Will Roberts.

    Comment?

  6. Multiparametric cardiac magnetic resonance imaging (CMR) for the...Read the original story

    Friday Mar 10 | BioMed Central

    Endocarditis parietalis fibroplastica LA fflein is a rare form of primary restrictive cardiomyopathy with poor prognosis. It is generally caused by hypereosinophilic syndrome with eosinophilic penetration of the heart.

    Comment?

  7. Corbus To Present Gene Expression Data From Recent Phase II Systemic...Read the original story

    Tuesday Mar 7 | BioSpace

    The data were obtained from analyses of skin biopsies taken from systemic sclerosis patients before and after 12 weeks of treatment with JBT-101 in the Company's recently completed Phase 2 study in diffuse cutaneous systemic sclerosis . The presentation will be on March 13, 2017, in New York City, at the Research and Development Day hosted by Corbus .

    Comment?

  8. Corbus Pharmaceuticals to Present Gene Expression Data from Recent...Read the original story w/Photo

    Wednesday Mar 8 | Market Wire

    The data were obtained from analyses of skin biopsies taken from systemic sclerosis patients before and after 12 weeks of treatment with JBT-101 in the Company's recently completed Phase 2 study in diffuse cutaneous systemic sclerosis . The presentation will be on March 13, 2017, in New York City, at the Research and Development Day hosted by Corbus .

    Comment?

  9. The effects of 1,4-dimethylpyridine in metastatic prostate cancer in miceRead the original story w/Photo

    Monday Mar 6 | BioMed Central

    We previously showed that 1-methylnicotinamide and its analog 1,4-dimethylpyridine could inhibit the formation of lung metastases and enhance the efficacy of cyclophosphamide-based chemotherapy in the model of spontaneously metastasizing 4T1 mouse mammary gland tumors. In the present study, we aimed to investigate whether the previously observed activity of pyridine compounds pertains also to the prevention and the treatment of metastatic prostate tumors, in a combined chemotherapy with docetaxel.

    Comment?

  10. NYU Langone Medical Center Release: Available Drug May Protect...Read the original story

    Monday Mar 6 | BioSpace

    Female mice treated with everolimus, along with chemotherapy, were found to have more than twice as many offspring afterward as mice treated with the chemotherapy alone. Such strong results with an available drug, say the study authors, may speed the process of applying for permission to test it in premenopausal cancer patients.

    Comment?

  11. Tumour drug may prevent infertility caused by chemotherapyRead the original story w/Photo

    Tuesday Mar 7 | The Daily Millbury

    The results of the study argue that everolimus may represent a fertility-sparing drug treatment to complement the freezing of eggs and embryos, which are valued methods, but time-consuming, A drug used to slow tumour growth may also prevent infertility caused by standard chemotherapy used for breast cancer treatment, according to a study. The study, conducted on mice, found that the drug everolimus protects ovaries from cyclophosphamide - a chemotherapy used often against breast cancer but known to deplete the supply of egg cells needed to achieve pregnancy.

    Comment?

  12. Available drug may protect ovaries and fertility from damage by chemotherapiesRead the original story w/Photo

    Tuesday Mar 7 | Medical News Today

    A drug already used to slow tumor growth may also prevent infertility caused by standard chemotherapies, according to a study in mice published online in the Proceedings of the National Academy of Sciences . Led by researchers from NYU Langone Medical Center, the study found that the drug everolimus protects ovaries from cyclophosphamide, a chemotherapy used often against breast cancer , but known to deplete the supply of egg cells needed to achieve pregnancy.

    Comment?

  13. Why Is Aurinia Pharmaceuticals A Definite Buy In 2017?Read the original story w/Photo

    Monday Mar 6 | Seeking Alpha

    Based on 24-week data, Voclosporin proved to be the first investigational drug to meet all primary and secondary endpoints of the global phase 2 trial in Lupus Nephritis indication. The 48-week data from AURA-LV trial has further reiterated the superior clinical profile of the drug and allayed all fears related to the safety profile of the drug.

    Comment?

  14. Lupus Nephritis Market Research Report by Regional Analysis: Forecast 2023Read the original story w/Photo

    Monday Mar 6 | SBWire

    Global Lupus Nephritis Market Lupus nephritis refers to the kidney damage caused by the disease lupus erythematosus. Lupus erythematosus is an autoimmune disease where the immune system turns against the body, affecting vital organs.

    Comment?

  15. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and...Read the original story

    Monday Mar 6 | CiteULike

    Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of patients with triple-negative breast cancer .

    Comment?

  16. Membranous Lupus Nephritis: The Same, But Different.Read the original story

    Thursday Mar 2 | CiteULike

    American journal of kidney diseases : the official journal of the National Kidney Foundation , Vol. 68, No.

    Comment?

  17. Current and Emerging Therapies for Lupus Nephritis.Read the original story

    Thursday Mar 2 | CiteULike

    The introduction of corticosteroids and later, cyclophosphamide dramatically improved survival in patients with proliferative lupus nephritis, and combined administration of these agents became the standard-of-care treatment for this disease. However, treatment failures were still common and the rate of progression to ESRD remained unacceptably high.

    Comment?

  18. Juno Finally Drops Problem CAR-T Drug That Caused DeathsRead the original story

    Wednesday Mar 1 | BioSpace

    "2016 was a year of progress and learning for Juno and the cancer immunotherapy field. We continue to experience encouraging signs of clinical benefit in our trial addressing NHL, but we also recognize the unfortunate and unexpected toxicity we saw in our trial addressing ALL with JCAR015.

    Comment?

  19. Calcineurin inhibitors versus cyclophosphamide for idiopathic...Read the original story

    Thursday Mar 2 | CiteULike

    To compare the efficacy and safety of calcineurin inhibitors with cyclophosphamide in the treatment of idiopathic membranous nephropathy . A literature search was carried out using PubMed, EMBASE, Cochrane Central Register of Controlled Trials , and three Chinese databases from inception through June 2016.

    Comment?

  20. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.Read the original story

    Thursday Mar 2 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. The majority of children who present with their first episode of nephrotic syndrome achieve remission with corticosteroid therapy.

    Comment?